A clinical case of polymyalgia rheumatica in a patient with postmenopausal osteoporosis
https://doi.org/10.37586/2686-8636-2-2026-220-225
Abstract
Polymyalgia rheumatica (PMR) is a chronic disease affecting the musculoskeletal system in patients over 50 years of age and is characterized by bilateral restriction of movement in the shoulder and hip joints, as well as prolonged morning stiffness. This disease is characterized by an increase in the erythrocyte sedimentation rate and the concentration of C-reactive protein in the blood. A clinical case of PMR in a 67-year-old patient with postmenopausal osteoporosis, which complicates treatment with glucocorticoids, is described. In addition to the mandatory diagnostic criteria, additional signs were identified, the total of which amounted to 6 points: morning stiffness lasting more than 45 minutes (2 points), pain in the hip joints and limited mobility of those joints (1 point), absence of an increase in the level of rheumatoid factor in the blood serum (2 points), and the presence of ultrasound signs of synovitis and tenosynovitis of the long head of the biceps muscle in both shoulder joints (1 point). A positive trend in clinical condition and laboratory parameters was observed during the treatment of PMR with methylprednisolone. The monitored parameters of bone mineral density of the spine and femoral neck indicated that continuation of denosumab therapy for the prevention of recurrent fractures, initiated even before the diagnosis of PMR due to concomitant postmenopausal osteoporosis, was advisable during glucocorticoid administration.
About the Authors
L. V. SizovaRussian Federation
Sizova Lyudmila Victorovna, Cand. Sci. Med., Docent, Associate Professor at the Department of Polyclinic Therapy
Orenburg
T. A. Silkina
Russian Federation
Orenburg
References
1. Mahmood S. B., Nelson E., Padniewski J., Nasr R. Polymyalgia rheumatica: An updated review. Cleve Clin J Med. 2020 ; 87 (9) : 549–556. DOI: 10.3949/ccjm.87a.20008.
2. Bart B. Y., Kudina E. V., Larina V. N. Rheumatic polymyalgia: case report . Clin med. 2015 ; 93 (4) : 74–78. (In Russ.).
3. Manzo C., Castagna A., Ruotolo G. Can SARS-CoV-2 trigger relapse of polymyalgia rheumatica? Joint Bone Spine. 2021 ; 88 (3) : 105150. DOI: 10.1016/j.jbspin.2021.105150.
4. Ottaviani S., Juge P. A., Forien M., et al. Polymyalgia rheumatica following COVID-19 vaccination: A case-series of ten patients. Joint Bone Spine. 2022 ; 89 (2) : 105334. DOI: 10.1016/j.jbspin.2021.105334.
5. Carvajal Alegria G., Boukhlal S., Cornec D., Devauchelle-Pensec V. The pathophysiology of polymyalgia rheumatica, small pieces of a big puzzle. Autoimmun Rev. 2020 ; 19 (11) : 102670. DOI: 10.1016/j.autrev.2020.102670.
6. Florescu M. M., Bobircă F., Florescu A., et al. Polymyalgia rheumatica: An update (Review). Exp Ther Med. 2023 ; 26 (6) : 543. DOI: 10.3892/etm.2023.12242.
7. Teplova N. V., Putilina M. V., Chervyakova G. A., et al. Diffculties in differential diagnosis and modern approaches to treatment of polymyalgia rheumatica. Medical alphabet. 2022 ; (1) : 29-34. (In Russ.). DOI: 10.33667/2078-5631-2022-1-29-34.
8. Reitsema R. D., Jiemy W. F., Wekema L., et al. Contribution of pathogenic T helper 1 and 17 cells to bursitis and tenosynovitis in polymyalgia rheumatica. Front Immunol. 2022 ; 13 : 943574. DOI: 10.3389/fimmu.2022.943574.
9. Lundberg I. E., Sharma A., Turesson C., Mohammad A. J. An update on polymyalgia rheumatica. J Intern Med. 2022 ; 292 (5): 717–732. DOI: 10.1111/joim.13525.
10. Figus F. A., Skoczyńska M., McConnell R., et al. Imaging in polymyalgia rheumatica: which technique to use? Clin Exp Rheumatol. 2021 ; 39 (4) : 883–888. DOI: 10.55563/clinexprheumatol/5qmpcb.
11. Satybaldyev A. M., Demidova N. V., Savushkina N. M., Gordeev A. V. Polymyalgia rheumatica. Rheumatology Science and Practice. 2018 ; 56 (2) : 215–227. (In Russ.). DOI: 10.14412/1995-4484-2018-215-227.
12. Svetlova M. S. Rheumatic polymyalgia: clinic, diagnosis, principles of therapy (to help the primary care physician). Medical Council. 2021 ; (4) : 164–169. (In Russ.). DOI: 10.21518/2079-701X-2021-4-164-169.
13. Colombo M. G., Wetzel A. J., Haumann H., et al. Polymyalgia rheumatica. Dtsch Arztebl Int. 2022 ; 119 (24) : 411–417. DOI: 10.3238/arztebl.m2022.0218.
14. Raleigh M. F., Stoddard J., Darrow H. J. Polymyalgia Rheumatica and Giant Cell Arteritis: Rapid Evidence Review. Am Fam Physician. 2022 ; 106 (4): 420–426.
15. Nasonov E. L., Satybaldyev A. M., Otteva E. N., et al. Pharmacotherapy of giant cell arteritis and polymyalgia rheumatica: Prospects for the use of monoclonal antibodies to interleukin 6. Rheumatology Science and Practice. 2024 ; 62 (4) : 348–364. (In Russ.). DOI: 10.47360/1995-4484-2024-348-364.
16. Meshkov A. D., Maslyansky A. L., Bulanov N. M., et al. Experience with olokizumab in the treatment of polymyalgia rheumatica and giant cell arteritis: A series of cases. Rheumatology Science and Practice. 2024 ; 62 (4) : 431–434 (In Russ.). DOI: 10.47360/1995-4484-2024-431-434.
17. Iorio L., Bond M., Padoan R., Dejaco C. Advances in the treatment of polymyalgia rheumatica. Rheumatology (Oxford). 2025 ; 64 (Supplement_1) : i48–i54. DOI: 10.1093/rheumatology/keae539.
18. Sokhal B. S., Hider S. L., Paskins Z., et al. Fragility fractures and prescriptions of medications for osteoporosis in patients with polymyalgia rheumatica: results from the PMR Cohort Study. Rheumatol Adv Pract. 2021 ; 5 (3) : rkab094. DOI: 10.1093/rap/rkab094.
19. Vinicki J. P., Cusa A., Domingo D., et al. Effectiveness of methotrexate and leflunomide as corticoid-sparing drugs in patients with polymyalgia rheumatica. Rheumatol Adv Pract. 2024 ; 8 (2) : rkae033. DOI: 10.1093/rap/rkae033.
20. Toroptsova N. V., Nikitinskaya O. A., Nasonov E. L. To the 100th anniversary of the birth of academician V. A. Nasonova. Osteoporosis: Yesterday, today, tomorrow. Rheumatology Science and Practice. 2023 ; 61 (3) : 249–259. (In Russ.). DOI:10.47360/1995-4484-2023-249-259.
21. Wang W. Y., Chen L. H., Ma W. J., You R. X. Drug efficacy and safety of denosumab, teriparatide, zoledronic acid, and ibandronic acid for the treatment of postmenopausal osteoporosis: a network meta-analysis of randomized controlled trials. Eur Rev Med Pharmacol Sci. 2023 ; 27 (17) : 8253–8268. DOI: 10.26355/eurrev_202309_33586.
22. Shangguan L., Ding M., Wang Y., et al. Denosumab ameliorates osteoarthritis by protecting cartilage against degradation and modulating subchondral bone remodeling. Regen Ther. 2024 ; 27 : 181–190. DOI: 10.1016/j.reth.2024.03.019.
Review
For citations:
Sizova L.V., Silkina T.A. A clinical case of polymyalgia rheumatica in a patient with postmenopausal osteoporosis. Russian Journal of Geriatric Medicine. 2026;(2):220-225. (In Russ.) https://doi.org/10.37586/2686-8636-2-2026-220-225
JATS XML



















